만성 폐쇄성 폐질환(COPD) 치료 시장 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at USD 20.35 Bn in 2025 and is expected to reach USD 30.41 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.

Figure. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Region 2025

Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis. Key causes of COPD include tobacco smoking, exposure to lung irritants in the workplace like dusts and fumes, and air pollution. The main symptoms of COPD include shortness of breath, cough, mucus (sputum) production, and wheezing. As COPD progresses, lung function deteriorates over time, resulting in breathlessness.

Market Dynamics:

Global chronic obstructive pulmonary disease (COPD) treatment market growth is driven by factors such as high prevalence of tobacco smoking, increasing air pollution levels worldwide, rising geriatric population, and a growing awareness about the disease and available therapeutic options. However, lack of complete cure for COPD and related complications like lung cancer can hamper the market growth. Pharmaceutical companies investing in research and development of novel biologic drugs for COPD can offer lucrative opportunities for the market growth. Companies are developing epinephrine auto-injectors, bronchodilators, inhaled corticosteroids and combination therapies to effectively treat COPD symptoms and exacerbations.

Key Features of the Study:

• This report provides an in-depth analysis of the global chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this include AstraZeneca, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Sunovion Pharmaceuticals, Inc., CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Grifols, S.A., Almirall, S.A, Genentech, Inc
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global chronic obstructive pulmonary disease (COPD) treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation-

• By Drug Class:
  • Bronchodilators
  • Beta 2-Agonists
  • Anticholinergics
  • Theophyllines
  • Phosphodiesterase Type 4 Inhibitors
  • Corticosteroids
  • Others
• By Route of Administration:
  • Oral
  • Inhalation
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca
  • Orion Corporation
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Novartis AG
  • Sunovion Pharmaceuticals, Inc.
  • CHIESI Farmaceutici SpA
  • Alembic Pharmaceuticals Ltd
  • Verona Pharmaceuticals
  • Theravance Biopharma
  • Hoffmann-La Roche Ltd
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc
  • Grifols, S.A.
  • Almirall, S.A
  • Genentech, Inc

Table of Contents (TOC)

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Epidemiology
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Bronchodilators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Beta 2-Agonists
  • Anticholinergics
  • Theophyllines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Phosphodiesterase Type 4 Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inhalation
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • AstraZeneca*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Orion Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GSK plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sunovion Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CHIESI Farmaceutici SpA
  • Alembic Pharmaceuticals Ltd
  • Verona Pharmaceuticals
  • Theravance Biopharma
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc
  • Grifols, S.A.
  • Almirall, S.A
  • Genentech, Inc

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact